Beta Adrenergic Agonist Patent Application US20260109671A1
Summary
USPTO published patent application US20260109671A1 on April 23, 2026, filed September 24, 2025 under Application No. 19339240. The application covers chemical compounds for beta adrenergic agonist use and methods of treating diseases associated with adrenergic receptors. Inventors include Anthony P. Ford, Wei Chen, David Scott Carter, and Jiaxin Yu. CPC classifications indicate therapeutic applications for neurological conditions including A61P 25/16 (antiparkinson drugs) and A61P 25/28 (anti-Alzheimer agents).
“The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
USPTO published patent application US20260109671A1 for beta adrenergic agonist compounds and associated treatment methods. The application, filed September 24, 2025, covers chemical compounds for treating diseases associated with adrenergic receptors.
Pharmaceutical and biotechnology companies developing neurological therapies should monitor this publication for potential freedom-to-operate implications. Competitors in the beta-agonist or neurological disease space may need to evaluate whether their compounds or methods could conflict with the claimed inventions once the application proceeds to grant.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME
Application US20260109671A1 Kind: A1 Apr 23, 2026
Inventors
Anthony P. Ford, Wei Chen, David Scott Carter, Jiaxin Yu
Abstract
The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.
CPC Classifications
C07D 209/42 A61K 9/0019 A61K 9/0034 A61K 9/0073 A61P 25/16 A61P 25/28 A61P 25/30 C07D 213/38
Filing Date
2025-09-24
Application No.
19339240
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.